Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BCR
REST API REST API
Homo sapiens
BCR is differentially expressed in 264 experiments: 97 organism parts: amygdala, caudate nucleus, ... (95 more);, 146 disease states: normal, glioblastoma, ... (144 more);, 86 cell types 382 cell lines 35 compound treatments and 74 other conditions.
Synonyms D22S11, BCR1, D22S662, PHL, CML, ALL
Orthologs BCR (Bos taurus)   Bcr (Rattus norvegicus)   ENSCING00000005571 (Ciona intestinalis)   Bcr (Mus musculus)   BCR (Gallus gallus)   bcr (Xenopus laevis)   BCR (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, intracellular, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, ATP binding, GTPase activator activity, actin cytoskeleton organization, small GTPase mediated signal transduction, regulation of cell cycle, negative regulation of cell migration, regulation of small GTPase mediated signal transduction, response to lipopolysaccharide, Rho guanyl-nucleotide exchange factor activity, nucleotide binding, kinase activity, protein serine/threonine kinase activity, transferase activity, brain development, signal transduction, positive regulation of GTPase activity, negative regulation of inflammatory response, neuromuscular process controlling balance, inner ear morphogenesis, positive regulation of Rac GTPase activity, positive regulation of phagocytosis, Rac GTPase activator activity, protein phosphorylation, negative regulation of neutrophil degranulation
InterPro Term Bcr-Abl_oncoprot_oligo, C2_Ca-dep, Pleckstrin_homology, DH-domain, C2_membr_targeting, RhoGAP_dom
UniProt Accession P11274, A9UF05, A9UF04, A9UF01, E9PGJ4
Gene-Disease Assocation LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL, LEUKEMIA, CHRONIC MYELOID; CML
Search EB-eye ENSG00000186716
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (35 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
HL-60
2
E-GEOD-96, E-MTAB-37
Daudi
2
E-GEOD-96, E-MTAB-37
Jurkat
2
E-GEOD-1880, E-MEXP-2197
MCF-7
2
E-GEOD-20081, E-GEOD-3529
MDA468
2
E-MEXP-440, E-MTAB-62
376 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-20193, E-GEOD-3920, E-GEOD-4219, ... (44 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
endothelial cell
2
E-GEOD-3920, E-GEOD-19240
stromal cell
1
2
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
CD8+ effector memory RA T cell
1
E-TABM-40
hematopoietic progenitor cells
1
E-MEXP-70
80 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-3860, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, ... (47 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-GEOD-4412, E-MTAB-37, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
glial neoplasm
1
E-MTAB-62
myxoid liposarcoma
1
E-MTAB-62
carcinoma (undifferenciated)
1
E-MTAB-62
140 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1269, E-TABM-127, ... (25 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-412, E-GEOD-5824, E-GEOD-2803, E-TABM-868, E-TABM-782, ... (8 experiments)
ponasterone A
1
E-GEOD-3113
TNF
1
E-GEOD-15205
cigarette smoke
1
E-TABM-127
endotoxin
1
E-GEOD-3026
saline
1
E-GEOD-3026
29 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
ECACC
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1563, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147, E-GEOD-19665, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-17385, E-GEOD-20847, E-GEOD-6431

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-TABM-43, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-MEXP-1446, E-GEOD-22278, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-3720, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-5820, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.272 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM